Holmusk’s UK Managing Director, Caroline Gadd is attending NIHR MedTech Symposium 2022 today to share the impact that the company’s clinical decision support tool, MaST, had within an NHS Health Trust six months after implementation. The symposium is presented by the UK’s National Institute for Health and Care Research (NIHR) and focuses on the development, adoption and evaluation of new technologies for mental healthcare and dementia.

MaST (Management and Supervision Tool) provides visualizations using data from patients’ electronic health records (EHRs) in order to help mental health service providers with decision making and caseload management. One of the key features of MaST is its Risk of Crisis algorithm, which can identify service users at high risk of using mental health crisis services and helps ensure that patients get the right care at the right time.

At the conference, the team shared results from a study that compared several outcomes in the periods prior to and after MaST was implemented at Mersey Care NHS Foundation Trust as part of a transformation programme. In the period after MaST implementation, the following had occurred:

• Reduced duration of mental health crises

• Shorter inpatient hospital stays

• More crises managed in the community setting 

• Increase in the proportion of mental health service users who were contacted within 48 hours of discharge from hospital

This shift in activity from the hospital to the community setting was estimated to result in cost savings of about £1.7 million over the 6-month post-implementation period. 

“We are pleased to share that MaST has made an impact in helping to improve mental health care delivery,
 said Caroline Gadd, Managing Director of Holmusk UK. “Results like these provide evidence that we can successfully analyze clinical data from EHRs and provide actionable insights to support mental health service providers and enhance quality and safety of care for service users.”